Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wait For Me: AstraZeneca’s Durvalumab Gets Its Turn At The FDA

Executive Summary

The FDA has accepted for review AstraZeneca’s anti-PD-L1 product durvalumab in bladder cancer and granted it a priority review, setting the stage for its market debut in the second quarter of 2017. But as the fifth PD1/L1 targeting product to market it will need to attract attention to itself.

You may also be interested in...



Running The Drug Catalyst Gauntlet: What To Look For In Q2 2017

Neurotrope's novel bryostatin treatment for Alzheimer's, AstraZeneca's durvalumab in bladder cancer, and Actelion’s antibiotic cadazolid are among a raft of therapies scheduled for major data read-outs or approval decisions in Q2 2017. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at some crucial drug displays likely over the next three months.

Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field

Scrip spoke with five companies about their places in the crowded IO field in which big pharma and small biotech firms alike are seeking the best options for harnessing the immune system to fight cancer.

Bristol Still Rules Immuno-Oncology, But For How Long?

At $920m, sales for Opdivo still overshadow competitors, but market dynamics are set to change with introduction of Merck's Keytruda in first-line lung cancer and Roche's Tecentriq in second-line lung.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC097851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel